Literature DB >> 7699456

Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.

W A Breeman1, D J Kwekkeboom, P P Kooij, W H Bakker, L J Hofland, T J Visser, G J Ensing, S W Lamberts, E P Krenning.   

Abstract

UNLABELLED: To increase the target-to-background ratio in receptor scintigraphy, we hypothesized that receptor scintigraphy is best performed using the lowest possible mass with the highest possible specific radioactivity of the radioligand.
METHODS: Rats were injected with 2 or 10 micrograms of unlabeled octreotide or 2 or 10 micrograms of 111In-pentetreotide. Scintigraphic images were then obtained from 10 min before to 20 min after the 111In injection.
RESULTS: In some instances, there was a significant increase in 111In uptake in somatostatin receptor-positive organs. In others, there was a significant decrease. Since no significant differences were found in background radioactivity in the percent dose uptake of 111In in receptor-negative organs, these data indicate that target-to-background ratios can be increased by the administration of nonradiolabeled peptides under select conditions.
CONCLUSION: The uptake of 111In-pentetreotide in somatostatin receptor-positive organs results in a tissue-specific bell-shaped function of the injected mass of the radiopharmaceutical. This curve may also apply to somatostatin receptor-positive tumors, the visualization of which may be enhanced by optimizing the mass of 111In-pentetreotide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7699456

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

Authors:  Jean-Mathieu Beauregard; Michael S Hofman; Grace Kong; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF.

Authors:  Heewa Kareem; Karl Sandström; Ronny Elia; Lars Gedda; Matti Anniko; Hans Lundqvist; Marika Nestor
Journal:  Tumour Biol       Date:  2010-01-30

3.  Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging.

Authors:  William M Rockey; Ling Huang; Kyle C Kloepping; Nicholas J Baumhover; Paloma H Giangrande; Michael K Schultz
Journal:  Bioorg Med Chem       Date:  2011-05-14       Impact factor: 3.641

4.  Characterization and evaluation of (64)Cu-labeled A20FMDV2 conjugates for imaging the integrin αvβ 6.

Authors:  Lina Y Hu; Nadine Bauer; Leah M Knight; Zibo Li; Shuanglong Liu; Carolyn J Anderson; Peter S Conti; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

5.  Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys.

Authors:  Heather L Kimmel; Jonathon A Nye; Ronald Voll; Jiyoung Mun; Jeffrey Stehouwer; Mark M Goodman; John R Votaw; F I Carroll; Leonard L Howell
Journal:  Synapse       Date:  2012-03-16       Impact factor: 2.562

6.  Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors.

Authors:  Maarten Brom; Lieke Joosten; Peter Laverman; Wim J G Oyen; Martin Béhé; Martin Gotthardt; Otto C Boerman
Journal:  Mol Imaging       Date:  2011-04       Impact factor: 4.488

7.  Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy.

Authors:  W H Bakker; W A Breeman; M E van der Pluijm; M de Jong; T J Visser; E P Krenning
Journal:  Eur J Nucl Med       Date:  1996-07

8.  Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

Authors:  Vladimir Tolmachev; Helena Wållberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-11       Impact factor: 9.236

9.  [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.

Authors:  Ganesan Vaidyanathan; Donna J Affleck; Xiao-Guang Zhao; Stephen T Keir; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2010

10.  Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.

Authors:  Magdalena Malm; Nina Kronqvist; Hanna Lindberg; Lindvi Gudmundsdotter; Tarek Bass; Fredrik Y Frejd; Ingmarie Höidén-Guthenberg; Zohreh Varasteh; Anna Orlova; Vladimir Tolmachev; Stefan Ståhl; John Löfblom
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.